NR2F2 and hepatocellular carcinoma: Indeed these new isoforms have been demonstrated to either increase or decrease canonical COUP-TFII activity in a cell-dependent manner: In hepatocellular carcinoma cells, COUP-TFII_V2 reduces the ability of COUP-TFII_V1 to activate CYP7A1, while in human embryonic stem cells they have been show to increase the activity of the longest isoform [40,41]; given the lack of a DBD, we may hypothesize that they might compete for the binding of co-repressors or co-activators, but how they truly act is still unknown.